RIM
BMY.RT

Rockbridge Investment Management’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Rockbridge Investment Management’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-19
Closed – – 776
2020
Q4 		$0 Hold
19
– – ﹤0.01% 721
2020
Q3 		$0 Hold
19
– – ﹤0.01% 692
2020
Q2 		$0 Buy
+19
New +$69 ﹤0.01% 645

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

Rockbridge Investment Management's BMY.RT Position: Q1 2021 in Review

Rockbridge Investment Management sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 19 shares.

Rockbridge Investment Management first reported a position in BMY.RT in Q2 2020 and held it in 3 quarters. The position peaked at $0 in Q4 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Rockbridge Investment Management reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Rockbridge Investment Management sold 19 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021.
  • Rockbridge Investment Management first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q2 2020 and held it in 3 quarters.
  • Rockbridge Investment Management's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $0 in Q4 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Rockbridge Investment Management's 13F filing for Q1 2021, filed 20 May 2021.